Yervoy Bristol-Myers Squibb Australia Pty Ltd
Product name
Yervoy
Accepted date
Jul-2024
Active ingredients
Ipilimumab
Proposed indication
YERVOY in combination with nivolumab is indicated for the treatment of patients with unresectable or metastatic colorectal cancer
Application type
C (new indication)
Publication date
Jul-2024